Discover Algeria | Press area | Contact  
English Français
Registration
English Français

October 28, 2024 | 2 months ago

  • More options

    Share on LinkedIn
    Share on Twitter

Pharmaceutical industry: major steps forward in bioequivalence

Algeria is reinforcing its capacity to carry out the bioequivalence studies required to register locally-produced medicines.

Algeria Invest
Legal Notices | Terms of Services
news-detail

Algeria's public pharmaceutical group Saidal has conducted the country's first local bioequivalence study, validating the therapeutic efficacy of a generic antibiotic, amoxicillin, at its Equival Biocenter. This ground-breaking initiative represents a significant step towards pharmaceutical independence by strengthening the credibility of locally produced generic medicines. The Minister of Industry and Pharmaceutical Production, Ali Aoun, hailed this achievement, stressing the importance of this centre in guaranteeing patients equivalence between generic and reference medicines.


During the event, he also revealed that a second bioequivalence centre, owned by the private Clinica Group, had been approved to collaborate with PRU in Jordan, accredited by European and American authorities. Clinica aims to support Algeria's competitiveness on international markets by providing bioequivalence studies in line with international standards.


October 28, 2024 | algeria-logo

  • More options

    Share on LinkedIn
    Share on Twitter
Subscribe to the economic newsletter